3 days popular7 days popular1 month popular3 months popular

Combo therapy with lower intensity statin may be an alternative to higher-intensity monotherapy for some patients

The recent American College of Cardiology and guidelines recommend initiating moderate or high-intensity statin for patients with low-density lipoprotein (LDL) of 4.91 mmol/L or greater to reduce their risk for atherosclerotic cardiovacualr disease (ASCVD), the leading cause of death for both men and women in the United States.

The challenge in clinical practice is that some patients do not respond to high-intensity and adverse effects are common. Researchers reviewed published evidence to compare the clinical benefits, adherence, and harms of a lower-intensity statin combined with another lipid-modifying medication (bile acid sequestrant, ezetimibe, fibrate, niacin, or w-3 fatty acid) with those of higher-intensity among adults at high risk for ASCVD. with bile acid sequestrants or ezetimibe decreased at least as well as higher-intensity monotherapy but data on adverse events was limited.

There was insufficient evidence regarding LDL cholesterol reduction when comparing moderated combination therapy with fibrates, niacin, or w-3 fatty acids. The researchers also found insufficient evidence to compare long-term clinical outcomes, such as mortality or acute coronary events. The full review will be published in Annals of Internal Medicine.


American College of Physicians